Literature DB >> 27439595

Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.

Keina Nagakita1, Katsuyoshi Takata1, Kohei Taniguchi1, Tomoko Miyata-Takata1, Yasuharu Sato1, Akira Tari2, Nobuhiko Ohnishi1, Mai Noujima-Harada1, Shizuma Omote1, Naoya Nakamura3, Masaya Iwamuro4, Yoshinobu Maeda5, Hiroyuki Okada4, Mitsune Tanimoto5, Tadashi Yoshino1.   

Abstract

The gastrointestinal (GI) tract is the most common primary site of extranodal diffuse large B-cell lymphoma (DLBCL), with approximately one-third of extranodal DLBCL occurring in the GI tract. We investigated the clinicopathological features and immunohistochemically-assessed cell-of-origin of 49 GI DLBCL cases (stomach, 24; small intestine, 10; colon, 15) and also examined the presence of MYD88 L265P as recently this mutation has been frequently identified in ABC-like DLBCL, particularly in extranodal sites. Small intestinal DLBCL was characterized by the preponderance of women (P = 0.041) and elevated LDH (P = 0.002) and soluble interleukin-2 receptor (P = 0.033). Small intestinal DLBCL more frequently showed anemia (P = 0.031) and elevated CRP (P = 0.029) than gastric DLBCL. ABC-like phenotype was seen in 71.4 % cases (stomach, 79 %; small intestine, 70 %; colon, 60 %). MYD88 L265P was detected in 6.1 % cases; all were primary gastric DLBCL with ABC-like phenotype but had no distinct clinicopathological features. In conclusion, GI DLBCL had different clinicopathological features according to the primary site especially in the small intestine. Also, MYD88 L265P had little involvement in GI DLBCL compared with other extranodal DLBCLs, suggesting that its pathogenesis might be different from that of organs with a high frequency of MYD88 L265P.
© 2016 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  MYD88 L265P; diffuse large B-cell lymphoma; gastrointestinal tract

Mesh:

Substances:

Year:  2016        PMID: 27439595     DOI: 10.1111/pin.12439

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  9 in total

1.  Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma.

Authors:  Zhengzi Qian; Leiyuan Chen; Xinyuan Wang; Yutian Kan; Yafei Wang; Yong Yu; Xiaofang Wang; Zhigang Zhao; Hongliang Yang; Peng Ge; Tingting Ding; Qiongli Zhai; Haifeng Zhao
Journal:  Clin Exp Med       Date:  2021-08-24       Impact factor: 3.984

2.  CD30 Expression in Oral and Oropharyngeal Diffuse Large B Cell Lymphoma, not Otherwise Specified.

Authors:  Ana Luísa Morais-Perdigão; Carla Isabelly Rodrigues-Fernandes; Gabriela Ribeiro Araújo; Ciro Dantas Soares; Bruno Augusto Benevenuto de Andrade; Manoela Domingues Martins; Pablo Agustin Vargas; Hélder Antônio Rebelo Pontes; Fábio Ramôa Pires; Rommel Mario Rodríguez Burbano; Felipe Paiva Fonseca
Journal:  Head Neck Pathol       Date:  2021-10-16

Review 3.  Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.

Authors:  Thomas A Ollila; Adam J Olszewski
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

4.  Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Ju-Han Lee; Hoiseon Jeong; Jung-Woo Choi; HwaEun Oh; Young-Sik Kim
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

5.  A Retrospective Analysis of Primary Gastrointestinal Non-Hodgkin Lymphomas: Clinical Features, Prognostic Factors and Treatment Outcomes.

Authors:  Chen Tian; Yueyang Li; Zehui Chen
Journal:  Onco Targets Ther       Date:  2020-06-10       Impact factor: 4.147

Review 6.  MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.

Authors:  Rongrong Chen; Lulu Wang; Lixia Zhu; Xiujin Ye
Journal:  Ther Adv Hematol       Date:  2022-01-31

7.  Efficacy and Safety of Cyclophosphamide Low-Dose Pre-Phase Chemotherapy in Diffuse Large B Cell Lymphoma with Gastrointestinal Involvement.

Authors:  Luca Guarnera; Federico Meconi; Roberto Secchi; Maria Rosaria Pascale; Fabiana Esposito; Annagiulia Zizzari; Vito Mario Rapisarda; Manuela Rizzo; Livio Pupo; Maria Cantonetti
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

8.  Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients.

Authors:  Haorui Shen; Zhang Wei; Daobin Zhou; Yan Zhang; Xiao Han; Wei Wang; Lu Zhang; Chen Yang; Jun Feng
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

Review 9.  Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.

Authors:  Tadashi Yoshino; Takehiro Tanaka; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2020-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.